Synthekine is proud to be chosen as one of this year's Fierce 15 winners! We are honored to be named as one of the most promising early-stage biotechnology companies in the industry. Thank you, Fierce Biotech, for recognizing the work of our amazing team and our mission to develop the next generation of #cytokine therapeutics. Learn more: https://lnkd.in/e85ZGXyY #Fierce152022 #Fierce15 #Biotech
Synthekine
Biotechnology Research
Menlo Park, California 7,807 followers
Synthekine a biotechnology company focused on discovery and developing best in class cytokine therapeutics
About us
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.
- Website
-
http://www.synthekine.com
External link for Synthekine
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Menlo Park, California
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
1505 Obrien Drive
Suite A/D
Menlo Park, California 94025, US
Employees at Synthekine
Updates
-
This Saturday, our Chief Scientific Officer, Martin Oft, M.D., will be sharing key insights from the Phase 1 study of STK-012, our first-in-class α/β-biased IL-2 partial agonist for the treatment of advanced solid tumors, at “The Promise of Interleukin-2 Therapy Conference” in Paris, France. Join us in hearing Dr. Oft discuss STK-012 and its potential to improve the treatment paradigm for patients with #cancer. Learn more: https://bit.ly/4fX4lz8
-
Today, we announced that the U.S. #FDA has granted Fast Track designation to SYNCAR-001 + STK-009, our CD19 #CART and orthogonal IL-2 investigational therapy, for the treatment of patients with severe, refractory systemic #lupus erythematosus (SLE), without the use of lymphodepletion. Fast Track designation validates the urgent need for safer, more tailored therapies that offer the benefits of CAR-T without the added risks of #lymphodepletion. We’re highly encouraged by the FDA’s decision, which brings us one step closer to providing our novel treatment option to a broad SLE patient population. Learn more about the announcement here: https://lnkd.in/dNVPfgAB
-
#DYK Lung cancer is the leading cause of cancer death in the United States, accounting for an estimated 1 in 5 of all cancer deaths? On #WorldLungCancerDay, join us as we raise awareness and support the countless individuals and families impacted by lung cancer. Together, we can make a meaningful difference. #LungCancer #WLCD2024
-
This week, Alex Azrilevich, Pharm.D., our Vice President, Clinical Development, will be presenting on the promising potential of STK-012, our first-in-class α/β-biased IL-2 partial agonist for the treatment of advanced solid tumors, at the Kidney Cancer Research Summit hosted by KidneyCAN. Learn more: https://bit.ly/45RjH3r #KCRS24 #KidneyCancer
-
Our Scientific Founder, K. Christopher Garcia, Ph.D., was recently awarded the 2024 Passano Award for his research on the structural and mechanistic biology of cell surface receptors and its implications for safer and more effective treatments. Dr. Garcia’s research is foundational in our efforts to develop novel therapeutics targeting cytokine signaling pathways. Join us in congratulating Dr. Garcia on this prestigious honor! Learn more: https://bit.ly/4bLMokL
-
Next week, our VP of Business Development, Kunal Patel, will be joining a panel titled “A Licensing Deal for All Seasons” to discuss best practices for partnerships at the BIO International Convention in San Diego, CA. Don’t miss this opportunity to hear strategic insights for navigating #biotech partnerships from experts in the industry. Learn more: https://bit.ly/3V9JmAR #BIO2024
-
#BIO2024 is almost here! We look forward to gathering with the broader life sciences community where business and breakthroughs converge at the world’s largest #biotech gathering June 3-6 in San Diego, CA. Want to connect on-site? Send us a meeting request in the BIO partnering system: https://bit.ly/4dG5E4i
-
This week, Paul-Joseph (PJ) Aspuria, Ph.D., Senior Director, Cell Therapy, and Sandro Vivona, Ph.D., Senior Director, Biochemistry and BioPhysics will present on our innovative cytokine engineering technologies at the PEGS Boston Summit 2024. Learn more: https://lnkd.in/gTvzac3Q https://lnkd.in/gJXzsXYj #PEGS2024
-
As champions in innovation, we understand the importance of environmental stewardship in everything we do. Today, on #EarthDay, we reiterate our commitment to making a positive impact on the environment, from reducing our ecological footprint to promoting eco-friendly practices throughout our operations. Discover how we take meaningful action to protect our environment and promote a healthier future for all, below: